BOSTON SCIENTIFIC CORP

(c)

On October 25, 2024, Joseph F. Fitzgerald, our Executive Vice President and Group President, Cardiology, terminated a trading plan that was originally entered into on May 23, 2024 and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The plan covered the sale of up to 553,370 shares of our common stock, including up to 492,532 shares to be acquired upon exercise of stock options. Transactions under the plan were based upon pre-established dates and stock price thresholds.

On February 27, 2025, Mr. Fitzgerald entered into a new trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Fitzgerald’s plan covers the sale of 306,372 shares of our common stock to be acquired upon exercise of stock options. Transactions under Mr. Fitzgerald’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Fitzgerald’s plan will terminate on the earlier of December 31, 2025, or the date all shares subject to the plan have been sold.